NCT02672852View on ClinicalTrials.gov

BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment

PHASE3CompletedINTERVENTIONAL
Enrollment

507

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

August 2, 2017

Study Completion Date

July 26, 2018

Conditions
Psoriasis
Interventions
DRUG

Risankizumab

Risankizumab administered by subcutaneous injection

DRUG

Placebo

Placebo for risankizumab administered by subcutaneous injection

Sponsors

Lead Sponsor

AbbVie

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

AbbVie

INDUSTRY